BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.BioXcel Therapeutics' management team includes the following people: BioXcel Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. 10, 2020 at 9:12 a.m. BioXcel Therapeutics saw a increase in short interest in the month of August. Log in to see them here or sign up to get started.Create a list of the investments you want to track.Visit a quote page and your recently viewed tickers will be displayed here.There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics (BTAI), Microbot Medical ...[...]After Truist Financial and BMO Capital gave Bioxcel Therapeutics (NASDAQ: BTAI) a Buy rating last month, the company received another Buy, this time ...[...]BioXcel Therapeutics' (BTAI) CEO Vimal Mehta on Q2 2020 Results - Earnings Call TranscriptThere’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bioxcel Therapeutics (BTAI) and InMode ...[...]In a report released today, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on Bioxcel Therapeutics (BTAI), with a price target of ...[...]BioXcel Therapeutics rallies on positive BXCL501 dataBioXcel Therapeutics launches compassionate use program for BXCL501BioXcel Therapeutics (BTAI) Investor Presentation - SlideshowThere’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics (BTAI), Atara Biotherapeutics ...[...]Enrollment underway in study of BioXcel treatment of opioid withdrawalBioXcel Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business UpdateBioXcel Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business UpdateBioXcel Therapeutics to Host Second Quarter 2020 Operating and Financial Results Conference Call and WebcastBioXcel Therapeutics to Host Second Quarter 2020 Operating and Financial Results Conference Call and WebcastBioXcel Therapeutics to Participate in the Canaccord Genuity 40th Annual Growth ConferenceBioXcel Therapeutics to Participate in the Canaccord Genuity 40th Annual Growth ConferenceBioXcel Therapeutics Announces Pricing of Public Offering of Common StockBioXcel Therapeutics Announces Pricing of Public Offering of Common StockBioXcel Therapeutics Announces Proposed Public Offering of Common StockBioXcel Therapeutics Announces Proposed Public Offering of Common StockBioXcel Therapeutics Announces Primary and Secondary Endpoints Met in Two Pivotal Phase 3 Trials of BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar DisorderBioXcel Therapeutics Announces Primary and Secondary Endpoints Met in Two Pivotal Phase 3 Trials of BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar DisorderBioXcel Therapeutics Announces Compassionate Use Program at Massachusetts General Hospital for BXCL501 to Treat COVID-19 Patients Suffering from Delirium and AgitationBioXcel Therapeutics Announces Compassionate Use Program at Massachusetts General Hospital for BXCL501 to Treat COVID-19 Patients Suffering from Delirium and AgitationBioXcel Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Formulation for BXCL501 and Methods of Treating AgitationBioXcel Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Formulation for BXCL501 and Methods of Treating AgitationBioXcel Therapeutics Announces Appointment of Reina Benabou, M.D., Ph.D., as Chief Development OfficerBioXcel Therapeutics Announces Appointment of Reina Benabou, M.D., Ph.D., as Chief Development OfficerBioXcel Therapeutics Announces Appointment of William P. Kane as Chief Commercial OfficerBioXcel Therapeutics Announces Appointment of William P. Kane as Chief Commercial Officer Since then, BTAI shares have increased by 33.9% and is now trading at $39.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Want to see which stocks are moving? Some companies that are related to BioXcel Therapeutics include Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include (BTAI) raised $60 million in an initial public offering on Thursday, March 8th 2018. Biden and other Democrats accuse Trump of stoking racial tensions, encouraging violence Find the latest news headlines from BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.
The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.